Myriad Genetics CSO reports tax share withholding

Myriad Genetics Chief Scientific Officer Dale Muzzey reported a routine tax-related share withholding.

Accepted by SEC EDGAR 03/23/2026 - 04:23 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Myriad Genetics Chief Scientific Officer Dale Muzzey reported a routine tax-related share withholding. On March 22, 2026, 2,019 shares of Myriad Genetics common stock were withheld by the company at $4.58 per share to cover tax obligations from vesting restricted stock units.

These shares were not sold in the open market but delivered back to the issuer to satisfy taxes. After this tax-withholding disposition, Muzzey directly holds 327,256 shares of Myriad Genetics common stock, indicating the transaction affects only a small portion of his overall equity position.

Insider Trade Summary

Exercise Price or Tax Liability: 2,019 shares

Exercise Price or Tax Liability 1 txn

Insider Muzzey Dale

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	2,019	$4.58	$9K

Holdings After Transaction: Common Stock — 327,256 shares (Direct)

Footnotes (1)

1. F1. Represents shares of Common Stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the Reporting Person. The number of shares withheld was determined based on the closing price of Issuer's Common Stock on March 20, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did MYRIAD GENETICS INC (MYGN) report for Dale Muzzey?

MYRIAD GENETICS INC reported that Chief Scientific Officer Dale Muzzey had 2,019 shares of common stock withheld to cover tax obligations from vesting restricted stock units. This was a tax-withholding disposition, not an open-market sale, and was settled at $4.58 per share.

Was the MYGN insider transaction by Dale Muzzey an open-market sale of shares?

No, the MYGN transaction was not an open-market sale. The 2,019 shares were withheld by the company to satisfy tax withholding obligations on vesting restricted stock units, meaning the shares were delivered back to the issuer rather than sold on the market.

How many MYGN shares does Dale Muzzey hold after the reported Form 4 transaction?

After the tax-withholding disposition, Dale Muzzey directly holds 327,256 shares of MYRIAD GENETICS INC common stock. This shows the 2,019 withheld shares represent a small fraction of his overall holdings and reflects a routine tax-related adjustment rather than a significant position change.

What price was used to determine the MYGN shares withheld for Dale Muzzey’s taxes?

The number of MYGN shares withheld for Dale Muzzey’s tax obligations was based on the closing price of Myriad Genetics common stock on March 20, 2026, which was $4.58 per share. This price was used to calculate how many shares were needed to cover the taxes.

What does transaction code F mean in the MYGN Form 4 for Dale Muzzey?

Transaction code F in the MYGN Form 4 indicates a tax-withholding disposition. It means shares were delivered to the issuer to pay the exercise price or tax liability, here relating to vesting restricted stock units, rather than being bought or sold in the open market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Muzzey Dale

(Last) (First) (Middle)

322 NORTH 2200 WEST

(Street)

SALT LAKE CITY UTAH 84116

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MYRIAD GENETICS INC [ MYGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/22/2026		F		2,019(1)	D	$4.58	327,256	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of Common Stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the Reporting Person. The number of shares withheld was determined based on the closing price of Issuer's Common Stock on March 20, 2026.

Remarks:

	By: Justin Hunter For: Dale Muzzey	03/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)